MWNA
CNCE

Marshall Wace North America’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Marshall Wace North America’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-27,017
Closed -$378K – 1579
2017
Q2 		$378K Buy
+27,017
New +$398K ﹤0.01% 1134

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Marshall Wace North America's CNCE Position: Q3 2017 in Review

Marshall Wace North America sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2017, closing a stake of 27,017 shares — an estimated $378K sold.

Marshall Wace North America first reported a position in CNCE in Q2 2017 and held it in 1 quarter. The position peaked at $378K in Q2 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q3 2017.

  • Marshall Wace North America reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Marshall Wace North America sold 27,017 Concert Pharmaceuticals, Inc. shares in Q3 2017, an estimated $378K.
  • Marshall Wace North America first reported a position in Concert Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Marshall Wace North America's Concert Pharmaceuticals, Inc. position peaked at $378K in Q2 2017.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2017.

Based on Marshall Wace North America's 13F filing for Q3 2017, filed 13 Nov 2017.